Frances Varian, Jennifer Dick, Christian Battersby, Stefan Roman, Jenna Ablott, Lisa Watson, Sarah Binmahfooz, Hamza Zafar, Gerry Colgan, John Cannon, Jay Suntharalingam, Jim Lordan, Luke Howard, Colm McCabe, John Wort, Laura Price, Colin Church, Neil Hamilton, Iain Armstrong, Abdul Hameed, Judith Hurdman, Charlie Elliot, Robin Condliffe, Martin Wilkins, Alastair Webb, David Adlam, Ray L Benza, Kazem Rahimi, Mohadeseh Shojaei-Shahrokhabadi, Nan X Lin, James M S Wason, Alasdair McIntosh, Alex McConnachie, Jennifer T Middleton, Roger Thompson, David G Kiely, Mark Toshner, Alexander Rothman
Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inadequate response to dual therapy with a phosphodiesterase type-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended to either intensify oral therapy by adding a selective prostacyclin receptor (IP) agonist (selexipag), or switching from PDE5i to a soluble guanylate-cyclase stimulator (sGCS; riociguat)...
January 2024: Pulmonary Circulation